Mouth and Tooth Diseases

 187 Companies   337 Products   170 Mechanisms of Action   247 Trials 
321 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mouth and Tooth Diseases
NCT02258243: Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

Active, not recruiting
2
3
US
aminolevulinic acid hydrochloride, 5-ALA HCl, ALA HCl, aminolevulinic acid HCl, photodynamic therapy, Light Infusion Therapy™, PDT, therapy, photodynamic, laboratory biomarker analysis, questionnaire administration
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Basal Cell Carcinoma of the Skin, Nevoid Basal Cell Carcinoma Syndrome
10/16
12/17
Mouth and Tooth Diseases
NCT02441920: Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis

Terminated
N/A
400
NA
University of Birmingham, Dudley Group NHS Foundation Trust
Periodontitis, Rheumatoid Arthritis
11/12
11/12
Mouth and Tooth Diseases
NCT00932594: The New Serial Treatment of Temporomandibular Disorders

Recruiting
N/A
4
RoW
Adjust the TMJ Pressure to Normal Value, Do not adjust the pressure of TMJ
Sun Yat-sen University
Temporomandibular Disorder
12/18
12/26
Mouth and Tooth Diseases
NCT01141231: Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer

Active, not recruiting
3
240
US
Acupuncture
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Chemotherapy and Head/Neck Radiation, Radiation Toxicity, Xerostomia
11/19
11/20
Mouth and Tooth Diseases
NCT02211677: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma

Recruiting
N/A
720
RoW
Sun Yat-sen University
Nasopharyngeal Neoplasms, Blood Cell Count, Neoplasm Staging, Prognosis
12/19
12/24
Mouth and Tooth Diseases
NCT00588770: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
3
403
US, RoW
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Major Salivary Gland Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
06/18
02/26
2014-001274-34: Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers. Studio di fase II con abiraterone acetato nel paziente con tumore ricorrente/metastatico delle ghiandole salivari resistente al blocco ormonale completo.

Ongoing
2
24
Europe
Abiraterone Acetato, Tablet, Zytiga
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Janssen-Cilag SpA
relapsed and/or metastatic, castration resistant, salivary gland cancer tumore delle ghiandole salivari resistente alla castrazione, ricorrente e/o metastatico, relapsed and/or metastatic, castration resistant, salivary gland cancer tumore delle ghiandole salivari resistente alla castrazione, ricorrente e/o metastatico, Diseases [C] - Cancer [C04]
 
 
2014-003227-21: Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract Studio di fase 2 con Inlyta® (Axitinib) nel tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico

Ongoing
2
26
Europe
Axitinib, AG-013736, Coated tablet, Inlyta
Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Pfizer Italy
recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, Diseases [C] - Cancer [C04]
 
 
2018-000682-36: cabozantinib for salivary gland cancer patients cabozantinib voor speekselklierkanker

Ongoing
2
43
Europe
Cabometyx, Tablet, Cabometyx
Radboud university medical center, Ipsen
Salivary gland cancer Speekselklierkanker, salivary gland cancer Speekselklierkanker, Diseases [C] - Cancer [C04]
 
 
NCT02749903: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Active, not recruiting
2
46
US
enzalutamide
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Astellas Pharma US, Inc.
Salivary Cancer
02/19
07/22
2019-003857-27: Radioactive labeled PSMA therapy for advanced salivary gland cancer Radioactief gelabeld PSMA therapie voor gevorderde speekselkleirkanker.

Not yet recruiting
2
10
Europe
Lutetium-177-PSMA-I&T, Lutetium-177-PSMA-I&T, Solution for injection
Radboudumc, KWF dutch cancer society
Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma. Speekselklierkanker. Meer specifiek twee subtypen: adenoid cysteus carcinoom en salivary duct carcinoom., Two subtypes of salivary gland cancer Twee vormen van speekselklierkanker, Diseases [C] - Cancer [C04]
 
 
NCT03146650: Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Active, not recruiting
2
25
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Northwestern University, Bristol-Myers Squibb, National Cancer Institute (NCI)
Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVC Major Salivary Gland Carcinoma
02/21
08/25
NCT05008237: Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

Active, not recruiting
2
42
RoW
docetaxel plus Cisplatin
Samsung Medical Center
Salivary Gland Cancer
05/22
05/23
LUPSA, NCT04291300: Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Completed
2
12
Europe
Lutetium-177-PSMA-I&T, Lutetium-177 Prostate Specific Membrane Antigen
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma
02/23
02/23
NCT02091141: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Checkmark ASCO 2016
Jun 2016 - Jun 2016: ASCO 2016
Checkmark ASCO-GI 2016
Jan 2016 - Jan 2016: ASCO-GI 2016
Completed
2
673
US
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Erlotinib, Tarceva, Vemurafenib, Zelboraf, Cobimetinib, Cotellic, Vismodegib, Erivedge, Alectinib, Alecensa, Atezolizumab, Tecentriq
Genentech, Inc.
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
05/23
05/23
EORTC-1206, NCT01969578 / 2013-000314-38: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Completed
2
149
Europe
bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC
Salivary Gland Cancer
08/23
02/24
NCT05010629: 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Active, not recruiting
2
35
US
9-ING-41, Carboplatin, Paraplatin
Glenn J. Hanna, Actuate Therapeutics Inc.
Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
06/24
08/25
DISCOVARY, NCT05694819: Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma

Active, not recruiting
2
56
Japan
Darolutamide, Goserelin
National Cancer Center Hospital East, Bayer Yakuhin, Ltd.
Salivary Gland Cancer
08/24
02/26
NCT05074940: Amivantamab in Adenoid Cystic Carcinoma

Active, not recruiting
2
18
US
Amivantamab
Trisha Wise-Draper
Salivary Gland Cancer
08/25
08/28
iPRIME, NCT03360890: Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

Suspended
2
46
US
Pembrolizumab, Keytruda, Docetaxel, taxotere
University of Chicago
Thyroid Cancer, Salivary Gland Cancer
09/25
09/32
VUBAR, NCT03924466 / 2016-002164-13: Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

Recruiting
2
55
Europe
68GaNOTA-Anti-HER2 VHH1, HER2-PET/CT
Universitair Ziekenhuis Brussel, Kom Op Tegen Kanker, Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression, Salivary Gland Cancer, Gastric Cancer, Endometrial Cancer, Uterine Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Colorectal Cancer, Urothelial Carcinoma, Prostate Cancer
11/24
12/24
NCT04209660: Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Active, not recruiting
2
64
US
Lenvatinib, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Eisai Inc.
Adenoid Cystic Carcinoma, Salivary Gland Cancer
12/25
12/25
STARTRK-2, NCT02568267 / 2015-003385-84: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Checkmark From STARTRK-2 trial in NTRK+ solid tumors
Oct 2019 - Oct 2019: From STARTRK-2 trial in NTRK+ solid tumors
Checkmark STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Oct 2018 - Oct 2018: STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Checkmark Integrated analysis of 3 trials (STARTRK-2, STARTRK-1, ALKA-372-001) in NTRK fusion-positive solid tumors
More
Active, not recruiting
2
534
Europe, Japan, US, RoW
Entrectinib, RXDX-101
Hoffmann-La Roche
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
06/25
12/25
NCT05884320: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Recruiting
2
30
US
Sacituzumab Govitecan
M.D. Anderson Cancer Center, Gilead Sciences
Gland, Salivary Gland Cancers
12/25
12/26
NCT06695845: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Recruiting
2
200
US
Zanidatamab, ZW25, JZP598
Jazz Pharmaceuticals, Jazz Pharmaceuticals Ireland Limited
Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
12/26
12/27
NCT04620187: Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Recruiting
2
55
US
Ado-trastuzumab (T) emtansine (T-DM1), Kadcyla, Standard of Care Radiotherapy, Radiation, Standard of Care Chemotherapy, Cisplatin, carboplatin
Dana-Farber Cancer Institute, Genentech, Inc.
Salivary Gland Cancer, HER2 Gene Mutation
02/26
02/27
I-MAC, NCT06805617: A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Recruiting
2
35
US
Ivonescimab, SMT112, AK112
Glenn J. Hanna, Summit Therapeutics
Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
07/25
07/27
TROP2, NCT06923826: Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Not yet recruiting
2
32
RoW
Sacituzumab govitecan, Trodelvy
National University Hospital, Singapore, Gilead Sciences
Salivary Gland Cancer, Thyroid Cancer
04/30
04/30
NCT03172624: Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Completed
2
64
US
Nivolumab, Ipilimumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Salivary Gland Cancer
12/24
12/24
NCT04895735: MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Recruiting
2
45
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, Computerized axial tomography (procedure), Computerized Tomography (CT) scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, nuclear magnetic resonance imaging, sMRI, Structural MRI, PSMA PET Scan, Prostate-specific Membrane Antigen PET, PSMA PET, PSMA-Positron emission tomography
Mayo Clinic
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
06/25
06/26
NCT05898373: Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Not yet recruiting
2
120
NA
vedicitumomab (Edisil, RC48）, vedicitumomab in combination with pyrrolizidine, RC48 in combination with a platinum-based chemotherapeutic agent, RC48 in combination with teraplizumab
Peking Union Medical College
Salivary Gland Cancer
06/25
06/26
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark Approved for patients with MSI-H or dMMR tumors in five different types of cancer
Apr 2022 - Apr 2022: Approved for patients with MSI-H or dMMR tumors in five different types of cancer
More
Recruiting
2
1609
Europe, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
NCT05669664: Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Recruiting
2
21
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
04/27
04/27
NRG-HN010, NCT05408845: Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting
2
146
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
NRG Oncology, National Cancer Institute (NCI)
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
07/28
07/28
NCT02538510: Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Completed
1/2
50
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
University of Washington, National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage III Major Salivary Gland Carcinoma, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
09/19
09/23
NCT03602079: Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Completed
1/2
49
US
A166
Klus Pharma Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
01/22
01/22
NCI-2018-02473, NCT03749460: Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Completed
1/2
20
US
Nivolumab, 946414-94-4, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, CMAB819, Nivolumab Biosimilar CMAB819, Ipilimumab, 477202-00-9, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Biosimilar CS1002, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
University of Washington
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IVA Major Salivary Gland Cancer AJCC v8, Stage IVB Major Salivary Gland Cancer AJCC v8, Stage IVC Major Salivary Gland Cancer AJCC v8
11/22
11/23
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting
1/2
523
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
05/23
10/24
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
CAPS, NCT03781986: APG-115 in Salivary Gland Cancer Trial

Active, not recruiting
1/2
41
US
APG-115, Carboplatin
University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc.
Malignant Salivary Gland Cancer, Salivary Gland Cancer
06/25
12/25
NCT01846091: Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

Completed
1
12
US
Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, MV-NIS
Mayo Clinic, National Cancer Institute (NCI)
Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Head and Neck Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
09/19
11/19
NCT04249947: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Checkmark Interim results from P1 trial in mCRPC at ASCO-GU 2022
Feb 2022 - Feb 2022: Interim results from P1 trial in mCRPC at ASCO-GU 2022
Terminated
1
40
US
P-PSMA-101 CAR-T cells, Rimiducid
Poseida Therapeutics, Inc.
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
09/24
09/24
NCT01847326: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

Completed
1
48
US
carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, hydroxyurea, HU, HYD, Hydrea, Hydroxycarbamide, Hydurea, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation, hyperfractionated radiation therapy, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
01/24
01/24
NCT05553782: Drug Screening Using Novel IMD in ACC and Salivary Cancers

Not yet recruiting
1
20
US
Implantable Microdevice (IMD)
Dana-Farber Cancer Institute, Adenoid Cystic Carcinoma Research Foundation
Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma of the Salivary Gland
10/24
01/25
DASH, NCT04704661: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The Trial

Recruiting
1
51
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Ceralasertib, AZD6738, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
03/26
03/26
NCT04576091: Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Active, not recruiting
1
7
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8, Unresectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Unresectable Paranasal Sinus Squamous Cell Carcinoma, Unresectable Salivary Gland Squamous Cell Carcinoma
11/24
12/25
ADT-SCAN, NCT04214353: PSMA-PET Imaging Before and After ADT in Advanced SDC Patients

Recruiting
N/A
14
Europe
68Ga-PSMA-PET/CT, 18FDG-PET/CT
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma
05/23
09/23
NCT02245100: Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

Completed
N/A
130
US
Cytology specimen, Cytologic sampling, Laboratory biomarker analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
05/21
12/23
EARN, NCT06582849: Enhanced Assistance During Radiotherapy for Unmet Essential Needs

Recruiting
N/A
33
US
Standard assistance, Enhanced assistance
Washington University School of Medicine, American Society of Clinical Oncology
Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
12/25
12/25
NCT06686979: PDO Based Drug Sensitive Test in R/M SGC

Active, not recruiting
N/A
40
RoW
No Intervention: Observational Cohort
Huashan Hospital, Shanghai Cancer Hospital, China, Eye & ENT Hospital of Fudan University, Dongfang Hospital Affiliated to Tongji University, Shandong Cancer Hospital and Institute, Qilu Hospital of Shandong University, Shandong Provincial Hospital, Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China, Hospital of Stomatology, Wuhan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang University, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Zhejiang Cancer Hospital, Zhongnan Hospital Affiliated to Wuhan University, Shanghai Huangpu District Central Hospital
Salivary Gland Cancers, Patient Derived Organoid, Drug Sensitive Test in Vitro
11/26
11/28
INDAGA-UK, NCT06091878: Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers

Not yet recruiting
N/A
250
NA
Observation
Royal Marsden NHS Foundation Trust
Salivary Gland Cancer
01/25
01/26
NCT03942380: Cell-free Tumor DNA in Head and Neck Cancer Patients

Recruiting
N/A
500
Europe
Liquid biopsy
Christian von Buchwald, Copenhagen University Hospital, Denmark, Department of Otorhinolaryngology, Head and Neck Surgery and Audiology
Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Neoplasm, Oropharynx Carcinoma, Oral Cavity Cancer, Oral Cancer, Oral Neoplasm, Larynx Cancer, Larynx Carcinoma, Larynx Neoplasm, Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Neoplasm, Hypopharynx Cancer, Hypopharynx Neoplasm, Hypopharynx Carcinoma, Sinonasal Carcinoma, Thyroid Carcinoma, Thyroid Cancer, Thyroid Neoplasms, Salivary Gland Cancer, Salivary Gland Neoplasms, Salivary Gland Carcinoma, Sinonasal Cancer, Sinonasal Neoplasm
02/25
02/25
GEMS-001, NCT02069730: A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Active, not recruiting
N/A
114
Canada
Selinexor, KPT-330, EGFR or HER2 Inhibitor, Matched treatment, FGFR Inhibitor, C-KIT Inhibitor, Matched Treatment, Anti-androgen, NOTCH Inhibitor, MEK or PI3K Inhibitor
University Health Network, Toronto
Salivary Gland Cancer, Metastatic, Advanced, Recurrent
12/26
12/27
NCT01365169: Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Recruiting
N/A
590
US
Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma, Recurrent Colorectal Carcinoma, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Hypopharyngeal Carcinoma AJCC v7, Stage I Major Salivary Gland Cancer AJCC v7, Stage I Nasopharyngeal Carcinoma AJCC v7, Stage I Oral Cavity Cancer AJCC v6 and v7, Stage I Oropharyngeal Carcinoma AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC v6 and v7, Stage II Major Salivary Gland Cancer AJCC v7, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage II Oral Cavity Cancer AJCC v6 and v7, Stage II Oropharyngeal Carcinoma AJCC v6 and v7, Stage IIA Colorectal Cancer AJCC v7, Stage IIB Colorectal Cancer AJCC v7, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC v7, Stage III Laryngeal Cancer AJCC v6 and v7, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Oral Cavity Cancer AJCC v6 and v7, Stage III Oropharyngeal Carcinoma AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC v7, Stage IVA Laryngeal Cancer AJCC v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC v7, Stage IVB Laryngeal Cancer AJCC v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Carcinoma AJCC v7, Metastatic or Locally Unresectable Solid Tumor
06/27
06/27
ROOT, NCT04028479: The Registry of Oncology Outcomes Associated with Testing and Treatment

Completed
N/A
167
US
Biomarker Testing (L), Biomarker Testing, Molecular Testing, Next-generation sequencing (NGS), Multiplex molecular testing, Systemic Treatment (T), Biologic therapy, Targeted therapy, Immunotherapy, Chemotherapy, Patient Reported Outcomes (P), Patient experience, Quality of life, Self-reporting
Taproot Health
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
10/24
10/24
iCaRe2, NCT02012699: Integrated Cancer Repository for Cancer Research

Recruiting
N/A
999999
US
University of Nebraska
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
12/99
12/99
MAPS, NCT05087706: Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（）

Recruiting
N/A
182
RoW
Pyrotinib, Bicalutamide, Leuprorelin
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Salivary Gland Neoplasms
03/23
09/23
EURACAN, NCT05483374: The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers

Recruiting
N/A
13600
Europe, RoW
observation
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Associazione Italiana Oncologia Cervico Cefalica, Ministry of Health, Italy, European Union, Alleanza Contro il Cancro
Head and Neck Cancer, Nasopharynx Cancer, Nasal Cavity and Paranasal Sinus Cancer, Salivary Gland Cancer, Middle Ear Carcinoma
12/30
12/30
Mouth and Tooth Diseases
ChiCTR-TRC-12002325: Multi-center, randomized, double blind, placebo controlled study of the efficacy and safety of TGP in the treatment of pSS

Completed
4
330
 
TGP capsules (TGP) ;Placebo
China-Japan friendship Hospital Department of Rheumatism; Ningbo Lihua Pharmaceutical Company Limited, Ningbo Lihua Pharmaceutical Company Limited
Primary Sj?gren's Syndrome, pSS
 
 
2006-000991-34: A randomized, double-blind, monocentric phase IV clinical study on the ocular tolerability of a topical ophthalmic product containing Retinolpalmitat 1000 I.U. in comparison to a reference product containing Carbomer 0.2 % with repeated ocular applications over 12 months in 120 patients with keratoconjunctivitis sicca

Ongoing
4
120
Europe
Vitagel, Liposic, Vitagel, Liposic
Dr. Gerhard Mann, Chem-pharm. Fabrik GmbH
Patients suffering from keratoconjunctivitis sicca (dry eye) and break-up-time (BUT) values < 10 sec
 
 
2006-003391-35: Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögrens\' syndrome

Ongoing
4
65
Europe
Monofree Dexamethason 1mg/ml, Monofree Dexamethason 1mg/ml
Laboratoires THEA
keratoconjunctivitis sicca
 
 
ChiCTR-OIB-16007789: 0.1%Tacrolimus (FK506) in the treatment of sjogren's syndrome clinical efficacy evaluation

Recruiting
4
30
 
0.1% FK506 + 0.1% sodium hyaluronate eye drops Twice a day for 30 days
Eye Institute of Xiamen University; Eye Institute of Xiamen University, Senju Pharmaceutical Co., Ltd.
Sjogren's syndrome
 
 
CTRIPS, ChiCTR-IPR-15005990: Cyclosporine A in the Treatment of Interstitial Pneumonitis associated with Sjogren’s syndrome(): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial

Not yet recruiting
4
240
 
glucocorticoid+CsA ;glucocorticoid+placebo
Peking University People's Hospital; Level of the institution：, Hangzhou China-US East China pharmaceutical Co., Ltd.
Sjogren's syndrome
 
 
PromiseSS, ChiCTR-IPR-15005757: Prospective, Randomized, placebo-cOntrolled, double-blind, MultIcenter, parallel group Study to assess the Efficacy and safety of hydroxychloroquine in chinese patients with primary Sjogren's Syndrome

Not yet recruiting
4
400
 
Taking HCQ ;Nil
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Shanghai Zhongxi Pharmaceutical Co., Ltd.
primary Sjogren's Syndrome
 
 
ChiCTR-IPR-17013772: A Clinical Multi-center Study of Safety and Efficacy of Tacrolimus Eye Drops in Sjogren's Syndrome Dry Eye

Not yet recruiting
4
60
 
tacrolimus eye drops ;flurometholone eye drops
The Eye Hospital of Wenzhou Medical University; The Eye Hospital of Wenzhou Medical University, Supporting funds of the National Natural Science Foundation of China
Sjogren's Syndrome Dry Eye
 
 
ChiCTR1900022781: Follow-up study at four years after the end of clinical trial on the efficacy and safety of total glucosides of peony in the treatment of primary sjogren’s syndrome

Recruiting
4
180
 
TGP capsules
Department of Rheumatology and Immunology, Anhui Provincial Hospital; Ningbo Liwah Pharmaceutical Co., Ltd., Ningbo Liwah Pharmaceutical Co., Ltd.
Sjogren's Syndrome
 
 
ChiCTR1800019784: The metagenomic analysis of oral microflora in patients with primary Sjogren's syndrome before and after caries treatment and topical fluoridation

Recruiting
4
20
 
topical fluoridation; caries treatment ;topical fluoridation
Peking University School and Hospital of Stomatology; Peking University School and Hospital of Stomatology, Scientific research co-ordination fund
primary Sjogren's syndrome, dental caries
 
 
2021-001414-10: Response to corona vaccination in patients with primary Sjögren's syndrome

Ongoing
4
180
Europe
Dispersion for injection, Suspension for injection, Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]), COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
University Medical Center Groningen, Dutch Association of Sjögren patients (NVSP)
Primary Sjögren's syndrome, Primary Sjögren's syndrome, Diseases [C] - Immune System Diseases [C20]
 
 
ChiCTR1900022696: A prospective, controlled, randomized, open-label, single-center study for eramyd in the treatment of active sjogren's syndrome

Not yet recruiting
4
120
 
Iguratimod 25mg bid po ;hydroxychloroquine 0.2-0.4g/d+prednison0.2-0.5mg/kg.d
Shanghai Tongji Hospital; Shanghai Tongji Hospital, scientific research funds
Sjogren syndrome
 
 
ChiCTR2100052314: Effect of triamcinolone acetonide for parotid gland lavage on the salivary secretion of patients with Sjogren's syndrome

Not yet recruiting
4
54
 
Perfusing parotid gland with triamcinolone acetonide injection through parotid duct ;The parotid gland was perfused with normal saline through parotid duct
Affiliated Stomatological Hospital of Nanjing Medical University; Affiliated Stomatological Hospital of Nanjing Medical University, the National Natural Science Foundation of China (No. 81600908 and 81701491), the Nature Science Foundation of Jiangsu Province (No. BK2018040793 and BK20170152)
Sjogren syndrome
 
 
NCT04909255: Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Recruiting
4
50
RoW
mirabegron, Betmiga, oxybutynin, tolterodine, solifenacin, Ditropan, tartrate, vesicare
China Medical University Hospital
Sjogren's Syndrome, Overactive Bladder Syndrome
08/22
08/22
NCT04981145: The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Recruiting
4
78
RoW
Iguratimod Tablets, Hydroxychloroquine Sulfate Tablets
Second Affiliated Hospital, School of Medicine, Zhejiang University
Primary Sjögren's Syndrome
12/24
07/25
NCT05918406: Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

Completed
4
30
US
Nasal Guide
Oyster Point Pharma, Inc.
Dry Eye, Keratoconjunctivitis Sicca
08/23
08/23
NCT05700422: Nasal Spray Study in Sjogren's Dry Eye Disease

Completed
4
39
US
Varenicline Nasal Spray
University of Pennsylvania, Oyster Point Pharma, Inc.
Sjogren's Syndrome, Dry Eye
08/23
08/23
ChiCTR2500099615: Preliminary Study on the Clinical Efficacy and Mechanism of 0.05% Cyclosporine Eye Drops in the Treatment of Sj gren's Syndrome.

Completed
4
30
 
On top of the existing treatment, add 0.05% cyclosporine eye drops, four times a day.
Peking University First Hospital; Peking University First Hospital, Bethune Charitable Foundation, BCF
Sj gren's Syndrome
 
 
BRRPJS, NCT06410833: Belimumab After Rituximab in Resistant Primary Juvenile SS

Recruiting
4
15
RoW
Rituximab, Belimumab
Peking Union Medical College Hospital, Children's Hospital of Chongqing Medical University, Central South University, Shenzhen Children's Hospital, The First Hospital of Jilin University, Children's Hospital of The Capital Institute of Pediatrics, The Affiliated Hospital of Qingdao University, Children's Hospital of Nanjing Medical University, Children's Hospital of Fudan University, Shengjing Hospital, Shanghai Children's Hospital, Tianjin Children's Hospital
Sjogren's Syndrome, Pediatric ALL
12/25
12/26
NCT04835623: CEQUA for Sjogren's Syndrome Dry Eye

Completed
4
50
US
Cyclosporine 0.09% Ophthalmic Solution, Cequa Ophthalmic Product
Center for Ophthalmic and Vision Research, LLC, Sun Pharmaceutical Industries Limited
Dry Eye, Dry Eye Syndromes, Sjogren's Syndrome
03/24
03/24
RZVRheum, NCT05879419: Recombinant Herpes Zoster Vaccine in Patients with Autoimmune Rheumatic Diseases

Active, not recruiting
4
2005
RoW
Recombinant Herpes Zoster Vaccine (RZV), Shingrix®, MTX Discontinuation, MMF Discontinuation, Placebo, MTX maintain, MMF maintain
University of Sao Paulo General Hospital, GlaxoSmithKline
Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Vasculitis, Systemic, Juvenile Idiopathic Arthritis, Dermatomyositis, Juvenile, Behçet Disease
05/25
05/27
ChiCTR2200057578: Tofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trial

Not yet recruiting
4
120
 
Same dose of hydroxychloroquine sulfate as before ;Tofacitinib 5mg bid po+the same dose of hydroxychloroquine sulfate as before
Ningbo Medical Center Lihuili Hospital; Ningbo Medical Center Lihuili Hospital, Hisun biopharmaceutical.CO.,Ltd
Sjogren Syndrome
 
 
ChiCTR2300071950: Effect of acetylcysteine solution for salivary gland lavage on the salivary secretion of patients with Sjogren's syndrome

Not yet recruiting
4
51
 
Salivary gland irrigation with physiological saline through the opening of the salivary duct ;Salivary gland irrigation with acetylcysteine solution through the opening of the salivary duct ;N/A
The Fourth Affiliated Hospital of Nanjing Medical University ; The Fourth Affiliated Hospital of Nanjing Medical University, self-funding
Sjögren's syndrome
 
 
2014-003140-12: Leflunomide and Hydroxychloroquine combination therapy for primary Sjogren's Syndrome Leflunomide en Hydroxychloroquine combinatie therapie voor het primaire Syndroom van Sjogren

Ongoing
3
30
Europe
Leflunomide mylan, Plaquenil, Capsule, Leflunomide Mylan, Plaquenil
UMC Utrecht, ZonMw
Sjogren's Syndrome Syndroom van Sjogren, Sjogren's Syndrome Syndroom van Sjogren, Diseases [C] - Immune System Diseases [C20]
 
 
2017-001371-24: Intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies Immunoglobulines administrées par voie intraveineuse pour le traitement d’une neuropathie sensitive douloureuse compliquant un syndrome de Gougerot Sjögren primaire

Not yet recruiting
3
24
Europe
Solution for infusion, Privigen 100 mg/ml, solution pour perfusion
Hôpitaux Universitaires de Strasbourg, Hôpitaux universitaires de Strasbourg, CSL Behring
Primary Sjögren's syndrome associated painful sensory neuropathies Neuropathie sensitive douloureuse compliquant un syndrome de Gougerot Sjögren primaire, Primary Sjögren's syndrome associated painful sensory neuropathies Neuropathie sensitive douloureuse compliquant un syndrome de Gougerot Sjögren primaire, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-005687-22: A clinical study to investigate ianalumab is effective and safe in the treatment of active Sjögren`s syndrome

Ongoing
3
489
Europe
ianalumab, VAY736, Solution for injection in pre-filled syringe
Novartis Pharma AG, Novartis Pharma AG
Active Sjögren’s syndrome, Sjögren’s syndrome, Diseases [C] - Immune System Diseases [C20]
 
 
2020-005661-14: A clinical study to investigate if ianalumab is effective and safe in the treatment of active Sjögren`s syndrome

Ongoing
3
268
Europe
ianalumab, VAY736, Solution for injection in pre-filled syringe
Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Active Sjögren's syndrome, Sjögren's syndrome, Diseases [C] - Immune System Diseases [C20]
 
 
2022-002158-15: Treatment with tivanisiran for the dry eye in patients witht Sjögren Syndrome Tratamiento con tivanisirán para el ojo seco en pacientes con Síndrome de Sjögren

Not yet recruiting
3
200
Europe
Tivanisiran, SYL1001, Eye drops, solution
Sylentis SAU, Sylentis SAU
Dry Eye Disease Enfermedad de Ojo Seco, Ocular dryness Sequedad ocular, Diseases [C] - Eye Diseases [C11]
 
 
NCT04252209: the Effect of Mixture of Natural Products As Salivary Substitutes in Treatment Of Xerostomia

Completed
3
24
RoW
natural herbs of coconut, aloe vera, and pepperint, natural products, carboxy methyl cellulose, CMC
Cairo University
Sjogren's Syndrome, Xerostomia
11/22
03/23
NCT04819269: Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Completed
3
203
Europe, US
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
Sylentis, S.A.
Dry Eye Disease, Sjögren Syndrome
12/23
12/23
NCT06931041: Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial

Active, not recruiting
3
25
RoW
insulin lispro, Autologous serum
Instituto de Oftalmología Fundación Conde de Valenciana
Dry Eye, Sjogren Syndrome
06/25
06/25
HZNP-DAZ-303, NCT06245408: A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Recruiting
3
435
Europe, Canada, Japan, US, RoW
Dazodalibep, VIB 4920, MEDI4920, Placebo
Amgen
Sjögren's Syndrome (SS)
11/26
11/26
ARGX-113-2306, NCT06684847: A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome

Recruiting
3
580
US
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Primary Sjogrens Disease
07/27
07/28
DAFFODIL, NCT06741969: Nipocalimab in Moderate to Severe Sjogren's Disease

Recruiting
3
600
Europe, Japan, US, RoW
Nipocalimab, JNJ-80202135, JNJ-86507083, M281, Placebo, Standard of care treatment
Janssen Research & Development, LLC
Sjogrens Syndrome
01/28
05/30
NCT06747949: A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Recruiting
3
844
US
Dazodalibep, AMG 611
Amgen
Sjögren's Syndrome
08/29
08/29
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
506
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
TINISS, NCT03700138: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies

Recruiting
3
24
Europe
Privigen® 100mg/ml at the dose of 2g/kg of body weight, NaCl 0,9%
University Hospital, Strasbourg, France
Primary Sjögren's Syndrome Painful Sensory Neuropathies
12/25
07/26
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Recruiting
3
621
Europe, Canada, Japan, US, RoW
Dazodalibep, VIB 4920, MEDI 4920, Placebo
Amgen
Sjogren's Syndrome
08/26
08/26
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
POETYK SjS-1, NCT05946941: A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

Recruiting
3
756
Europe, Canada, Japan, US, RoW
Deucravacitinib, BMS-986165, Placebo
Bristol-Myers Squibb
Sjögren's Syndrome
11/26
11/28
NCT05673993: A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Active, not recruiting
3
381
RoW
Telitacicept 80 mg, RC 18 80 mg, Telitacicept 160 mg, RC 18 160 mg, Placebo
RemeGen Co., Ltd.
Primary Sjogren's Syndrome
12/27
06/28
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
NCT05005806: Fish Oil (Omega 3 ) in Sjogren's Syndrome

Completed
2/3
100
RoW
Omega 3 fatty acid, Placebo
Hawler Medical University
Sjogren's Syndrome
02/23
02/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mouth and Tooth Diseases
NCT02258243: Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

Active, not recruiting
2
3
US
aminolevulinic acid hydrochloride, 5-ALA HCl, ALA HCl, aminolevulinic acid HCl, photodynamic therapy, Light Infusion Therapy™, PDT, therapy, photodynamic, laboratory biomarker analysis, questionnaire administration
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Basal Cell Carcinoma of the Skin, Nevoid Basal Cell Carcinoma Syndrome
10/16
12/17
Mouth and Tooth Diseases
NCT02441920: Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis

Terminated
N/A
400
NA
University of Birmingham, Dudley Group NHS Foundation Trust
Periodontitis, Rheumatoid Arthritis
11/12
11/12
Mouth and Tooth Diseases
NCT00932594: The New Serial Treatment of Temporomandibular Disorders

Recruiting
N/A
4
RoW
Adjust the TMJ Pressure to Normal Value, Do not adjust the pressure of TMJ
Sun Yat-sen University
Temporomandibular Disorder
12/18
12/26
Mouth and Tooth Diseases
NCT01141231: Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer

Active, not recruiting
3
240
US
Acupuncture
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Chemotherapy and Head/Neck Radiation, Radiation Toxicity, Xerostomia
11/19
11/20
Mouth and Tooth Diseases
NCT02211677: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma

Recruiting
N/A
720
RoW
Sun Yat-sen University
Nasopharyngeal Neoplasms, Blood Cell Count, Neoplasm Staging, Prognosis
12/19
12/24
Mouth and Tooth Diseases
NCT00588770: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
3
403
US, RoW
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Major Salivary Gland Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
06/18
02/26
2014-001274-34: Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers. Studio di fase II con abiraterone acetato nel paziente con tumore ricorrente/metastatico delle ghiandole salivari resistente al blocco ormonale completo.

Ongoing
2
24
Europe
Abiraterone Acetato, Tablet, Zytiga
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Janssen-Cilag SpA
relapsed and/or metastatic, castration resistant, salivary gland cancer tumore delle ghiandole salivari resistente alla castrazione, ricorrente e/o metastatico, relapsed and/or metastatic, castration resistant, salivary gland cancer tumore delle ghiandole salivari resistente alla castrazione, ricorrente e/o metastatico, Diseases [C] - Cancer [C04]
 
 
2014-003227-21: Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract Studio di fase 2 con Inlyta® (Axitinib) nel tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico

Ongoing
2
26
Europe
Axitinib, AG-013736, Coated tablet, Inlyta
Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Pfizer Italy
recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, Diseases [C] - Cancer [C04]
 
 
2018-000682-36: cabozantinib for salivary gland cancer patients cabozantinib voor speekselklierkanker

Ongoing
2
43
Europe
Cabometyx, Tablet, Cabometyx
Radboud university medical center, Ipsen
Salivary gland cancer Speekselklierkanker, salivary gland cancer Speekselklierkanker, Diseases [C] - Cancer [C04]
 
 
NCT02749903: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Active, not recruiting
2
46
US
enzalutamide
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Astellas Pharma US, Inc.
Salivary Cancer
02/19
07/22
2019-003857-27: Radioactive labeled PSMA therapy for advanced salivary gland cancer Radioactief gelabeld PSMA therapie voor gevorderde speekselkleirkanker.

Not yet recruiting
2
10
Europe
Lutetium-177-PSMA-I&T, Lutetium-177-PSMA-I&T, Solution for injection
Radboudumc, KWF dutch cancer society
Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma. Speekselklierkanker. Meer specifiek twee subtypen: adenoid cysteus carcinoom en salivary duct carcinoom., Two subtypes of salivary gland cancer Twee vormen van speekselklierkanker, Diseases [C] - Cancer [C04]
 
 
NCT03146650: Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Active, not recruiting
2
25
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Northwestern University, Bristol-Myers Squibb, National Cancer Institute (NCI)
Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVC Major Salivary Gland Carcinoma
02/21
08/25
NCT05008237: Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

Active, not recruiting
2
42
RoW
docetaxel plus Cisplatin
Samsung Medical Center
Salivary Gland Cancer
05/22
05/23
LUPSA, NCT04291300: Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Completed
2
12
Europe
Lutetium-177-PSMA-I&T, Lutetium-177 Prostate Specific Membrane Antigen
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma
02/23
02/23
NCT02091141: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Checkmark ASCO 2016
Jun 2016 - Jun 2016: ASCO 2016
Checkmark ASCO-GI 2016
Jan 2016 - Jan 2016: ASCO-GI 2016
Completed
2
673
US
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Erlotinib, Tarceva, Vemurafenib, Zelboraf, Cobimetinib, Cotellic, Vismodegib, Erivedge, Alectinib, Alecensa, Atezolizumab, Tecentriq
Genentech, Inc.
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
05/23
05/23
EORTC-1206, NCT01969578 / 2013-000314-38: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Completed
2
149
Europe
bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC
Salivary Gland Cancer
08/23
02/24
NCT05010629: 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Active, not recruiting
2
35
US
9-ING-41, Carboplatin, Paraplatin
Glenn J. Hanna, Actuate Therapeutics Inc.
Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
06/24
08/25
DISCOVARY, NCT05694819: Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma

Active, not recruiting
2
56
Japan
Darolutamide, Goserelin
National Cancer Center Hospital East, Bayer Yakuhin, Ltd.
Salivary Gland Cancer
08/24
02/26
NCT05074940: Amivantamab in Adenoid Cystic Carcinoma

Active, not recruiting
2
18
US
Amivantamab
Trisha Wise-Draper
Salivary Gland Cancer
08/25
08/28
iPRIME, NCT03360890: Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

Suspended
2
46
US
Pembrolizumab, Keytruda, Docetaxel, taxotere
University of Chicago
Thyroid Cancer, Salivary Gland Cancer
09/25
09/32
VUBAR, NCT03924466 / 2016-002164-13: Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

Recruiting
2
55
Europe
68GaNOTA-Anti-HER2 VHH1, HER2-PET/CT
Universitair Ziekenhuis Brussel, Kom Op Tegen Kanker, Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression, Salivary Gland Cancer, Gastric Cancer, Endometrial Cancer, Uterine Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Colorectal Cancer, Urothelial Carcinoma, Prostate Cancer
11/24
12/24
NCT04209660: Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Active, not recruiting
2
64
US
Lenvatinib, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Eisai Inc.
Adenoid Cystic Carcinoma, Salivary Gland Cancer
12/25
12/25
STARTRK-2, NCT02568267 / 2015-003385-84: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Checkmark From STARTRK-2 trial in NTRK+ solid tumors
Oct 2019 - Oct 2019: From STARTRK-2 trial in NTRK+ solid tumors
Checkmark STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Oct 2018 - Oct 2018: STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Checkmark Integrated analysis of 3 trials (STARTRK-2, STARTRK-1, ALKA-372-001) in NTRK fusion-positive solid tumors
More
Active, not recruiting
2
534
Europe, Japan, US, RoW
Entrectinib, RXDX-101
Hoffmann-La Roche
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
06/25
12/25
NCT05884320: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Recruiting
2
30
US
Sacituzumab Govitecan
M.D. Anderson Cancer Center, Gilead Sciences
Gland, Salivary Gland Cancers
12/25
12/26
NCT06695845: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Recruiting
2
200
US
Zanidatamab, ZW25, JZP598
Jazz Pharmaceuticals, Jazz Pharmaceuticals Ireland Limited
Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
12/26
12/27
NCT04620187: Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Recruiting
2
55
US
Ado-trastuzumab (T) emtansine (T-DM1), Kadcyla, Standard of Care Radiotherapy, Radiation, Standard of Care Chemotherapy, Cisplatin, carboplatin
Dana-Farber Cancer Institute, Genentech, Inc.
Salivary Gland Cancer, HER2 Gene Mutation
02/26
02/27
I-MAC, NCT06805617: A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Recruiting
2
35
US
Ivonescimab, SMT112, AK112
Glenn J. Hanna, Summit Therapeutics
Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
07/25
07/27
TROP2, NCT06923826: Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Not yet recruiting
2
32
RoW
Sacituzumab govitecan, Trodelvy
National University Hospital, Singapore, Gilead Sciences
Salivary Gland Cancer, Thyroid Cancer
04/30
04/30
NCT03172624: Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Completed
2
64
US
Nivolumab, Ipilimumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Salivary Gland Cancer
12/24
12/24
NCT04895735: MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Recruiting
2
45
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, Computerized axial tomography (procedure), Computerized Tomography (CT) scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, nuclear magnetic resonance imaging, sMRI, Structural MRI, PSMA PET Scan, Prostate-specific Membrane Antigen PET, PSMA PET, PSMA-Positron emission tomography
Mayo Clinic
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
06/25
06/26
NCT05898373: Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Not yet recruiting
2
120
NA
vedicitumomab (Edisil, RC48）, vedicitumomab in combination with pyrrolizidine, RC48 in combination with a platinum-based chemotherapeutic agent, RC48 in combination with teraplizumab
Peking Union Medical College
Salivary Gland Cancer
06/25
06/26
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark Approved for patients with MSI-H or dMMR tumors in five different types of cancer
Apr 2022 - Apr 2022: Approved for patients with MSI-H or dMMR tumors in five different types of cancer
More
Recruiting
2
1609
Europe, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
NCT05669664: Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Recruiting
2
21
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201, Leuprolide Acetate, A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
04/27
04/27
NRG-HN010, NCT05408845: Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting
2
146
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
NRG Oncology, National Cancer Institute (NCI)
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
07/28
07/28
NCT02538510: Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Completed
1/2
50
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
University of Washington, National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage III Major Salivary Gland Carcinoma, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
09/19
09/23
NCT03602079: Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Completed
1/2
49
US
A166
Klus Pharma Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
01/22
01/22
NCI-2018-02473, NCT03749460: Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Completed
1/2
20
US
Nivolumab, 946414-94-4, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, CMAB819, Nivolumab Biosimilar CMAB819, Ipilimumab, 477202-00-9, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Biosimilar CS1002, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
University of Washington
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IVA Major Salivary Gland Cancer AJCC v8, Stage IVB Major Salivary Gland Cancer AJCC v8, Stage IVC Major Salivary Gland Cancer AJCC v8
11/22
11/23
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting
1/2
523
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
05/23
10/24
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
CAPS, NCT03781986: APG-115 in Salivary Gland Cancer Trial

Active, not recruiting
1/2
41
US
APG-115, Carboplatin
University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc.
Malignant Salivary Gland Cancer, Salivary Gland Cancer
06/25
12/25
NCT01846091: Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

Completed
1
12
US
Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, MV-NIS
Mayo Clinic, National Cancer Institute (NCI)
Estrogen Receptor Negative, Estrogen Receptor Positive, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Head and Neck Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
09/19
11/19
NCT04249947: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Checkmark Interim results from P1 trial in mCRPC at ASCO-GU 2022
Feb 2022 - Feb 2022: Interim results from P1 trial in mCRPC at ASCO-GU 2022
Terminated
1
40
US
P-PSMA-101 CAR-T cells, Rimiducid
Poseida Therapeutics, Inc.
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
09/24
09/24
NCT01847326: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

Completed
1
48
US
carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, paclitaxel albumin-stabilized nanoparticle formulation, ABI-007, nab paclitaxel, nab-paclitaxel, nanoparticle albumin-bound paclitaxel, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, hydroxyurea, HU, HYD, Hydrea, Hydroxycarbamide, Hydurea, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation, hyperfractionated radiation therapy, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
01/24
01/24
NCT05553782: Drug Screening Using Novel IMD in ACC and Salivary Cancers

Not yet recruiting
1
20
US
Implantable Microdevice (IMD)
Dana-Farber Cancer Institute, Adenoid Cystic Carcinoma Research Foundation
Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma of the Salivary Gland
10/24
01/25
DASH, NCT04704661: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The Trial

Recruiting
1
51
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Ceralasertib, AZD6738, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
03/26
03/26
NCT04576091: Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Active, not recruiting
1
7
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8, Unresectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Unresectable Paranasal Sinus Squamous Cell Carcinoma, Unresectable Salivary Gland Squamous Cell Carcinoma
11/24
12/25
ADT-SCAN, NCT04214353: PSMA-PET Imaging Before and After ADT in Advanced SDC Patients

Recruiting
N/A
14
Europe
68Ga-PSMA-PET/CT, 18FDG-PET/CT
Radboud University Medical Center, Dutch Cancer Society
Salivary Gland Cancer, Salivary Duct Carcinoma
05/23
09/23
NCT02245100: Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

Completed
N/A
130
US
Cytology specimen, Cytologic sampling, Laboratory biomarker analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
05/21
12/23
EARN, NCT06582849: Enhanced Assistance During Radiotherapy for Unmet Essential Needs

Recruiting
N/A
33
US
Standard assistance, Enhanced assistance
Washington University School of Medicine, American Society of Clinical Oncology
Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
12/25
12/25
NCT06686979: PDO Based Drug Sensitive Test in R/M SGC

Active, not recruiting
N/A
40
RoW
No Intervention: Observational Cohort
Huashan Hospital, Shanghai Cancer Hospital, China, Eye & ENT Hospital of Fudan University, Dongfang Hospital Affiliated to Tongji University, Shandong Cancer Hospital and Institute, Qilu Hospital of Shandong University, Shandong Provincial Hospital, Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China, Hospital of Stomatology, Wuhan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang University, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Zhejiang Cancer Hospital, Zhongnan Hospital Affiliated to Wuhan University, Shanghai Huangpu District Central Hospital
Salivary Gland Cancers, Patient Derived Organoid, Drug Sensitive Test in Vitro
11/26
11/28
INDAGA-UK, NCT06091878: Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers

Not yet recruiting
N/A
250
NA
Observation
Royal Marsden NHS Foundation Trust
Salivary Gland Cancer
01/25
01/26
NCT03942380: Cell-free Tumor DNA in Head and Neck Cancer Patients

Recruiting
N/A
500
Europe
Liquid biopsy
Christian von Buchwald, Copenhagen University Hospital, Denmark, Department of Otorhinolaryngology, Head and Neck Surgery and Audiology
Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Neoplasm, Oropharynx Carcinoma, Oral Cavity Cancer, Oral Cancer, Oral Neoplasm, Larynx Cancer, Larynx Carcinoma, Larynx Neoplasm, Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Neoplasm, Hypopharynx Cancer, Hypopharynx Neoplasm, Hypopharynx Carcinoma, Sinonasal Carcinoma, Thyroid Carcinoma, Thyroid Cancer, Thyroid Neoplasms, Salivary Gland Cancer, Salivary Gland Neoplasms, Salivary Gland Carcinoma, Sinonasal Cancer, Sinonasal Neoplasm
02/25
02/25
GEMS-001, NCT02069730: A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Active, not recruiting
N/A
114
Canada
Selinexor, KPT-330, EGFR or HER2 Inhibitor, Matched treatment, FGFR Inhibitor, C-KIT Inhibitor, Matched Treatment, Anti-androgen, NOTCH Inhibitor, MEK or PI3K Inhibitor
University Health Network, Toronto
Salivary Gland Cancer, Metastatic, Advanced, Recurrent
12/26
12/27
NCT01365169: Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Recruiting
N/A
590
US
Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma, Recurrent Colorectal Carcinoma, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Hypopharyngeal Carcinoma AJCC v7, Stage I Major Salivary Gland Cancer AJCC v7, Stage I Nasopharyngeal Carcinoma AJCC v7, Stage I Oral Cavity Cancer AJCC v6 and v7, Stage I Oropharyngeal Carcinoma AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC v6 and v7, Stage II Major Salivary Gland Cancer AJCC v7, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage II Oral Cavity Cancer AJCC v6 and v7, Stage II Oropharyngeal Carcinoma AJCC v6 and v7, Stage IIA Colorectal Cancer AJCC v7, Stage IIB Colorectal Cancer AJCC v7, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC v7, Stage III Laryngeal Cancer AJCC v6 and v7, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Oral Cavity Cancer AJCC v6 and v7, Stage III Oropharyngeal Carcinoma AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC v7, Stage IVA Laryngeal Cancer AJCC v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC v7, Stage IVB Laryngeal Cancer AJCC v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Carcinoma AJCC v7, Metastatic or Locally Unresectable Solid Tumor
06/27
06/27
ROOT, NCT04028479: The Registry of Oncology Outcomes Associated with Testing and Treatment

Completed
N/A
167
US
Biomarker Testing (L), Biomarker Testing, Molecular Testing, Next-generation sequencing (NGS), Multiplex molecular testing, Systemic Treatment (T), Biologic therapy, Targeted therapy, Immunotherapy, Chemotherapy, Patient Reported Outcomes (P), Patient experience, Quality of life, Self-reporting
Taproot Health
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
10/24
10/24
iCaRe2, NCT02012699: Integrated Cancer Repository for Cancer Research

Recruiting
N/A
999999
US
University of Nebraska
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
12/99
12/99
MAPS, NCT05087706: Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（）

Recruiting
N/A
182
RoW
Pyrotinib, Bicalutamide, Leuprorelin
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Salivary Gland Neoplasms
03/23
09/23
EURACAN, NCT05483374: The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers

Recruiting
N/A
13600
Europe, RoW
observation
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Associazione Italiana Oncologia Cervico Cefalica, Ministry of Health, Italy, European Union, Alleanza Contro il Cancro
Head and Neck Cancer, Nasopharynx Cancer, Nasal Cavity and Paranasal Sinus Cancer, Salivary Gland Cancer, Middle Ear Carcinoma
12/30
12/30
Mouth and Tooth Diseases
ChiCTR-TRC-12002325: Multi-center, randomized, double blind, placebo controlled study of the efficacy and safety of TGP in the treatment of pSS

Completed
4
330
 
TGP capsules (TGP) ;Placebo
China-Japan friendship Hospital Department of Rheumatism; Ningbo Lihua Pharmaceutical Company Limited, Ningbo Lihua Pharmaceutical Company Limited
Primary Sj?gren's Syndrome, pSS
 
 
2006-000991-34: A randomized, double-blind, monocentric phase IV clinical study on the ocular tolerability of a topical ophthalmic product containing Retinolpalmitat 1000 I.U. in comparison to a reference product containing Carbomer 0.2 % with repeated ocular applications over 12 months in 120 patients with keratoconjunctivitis sicca

Ongoing
4
120
Europe
Vitagel, Liposic, Vitagel, Liposic
Dr. Gerhard Mann, Chem-pharm. Fabrik GmbH
Patients suffering from keratoconjunctivitis sicca (dry eye) and break-up-time (BUT) values < 10 sec
 
 
2006-003391-35: Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögrens\' syndrome

Ongoing
4
65
Europe
Monofree Dexamethason 1mg/ml, Monofree Dexamethason 1mg/ml
Laboratoires THEA
keratoconjunctivitis sicca
 
 
ChiCTR-OIB-16007789: 0.1%Tacrolimus (FK506) in the treatment of sjogren's syndrome clinical efficacy evaluation

Recruiting
4
30
 
0.1% FK506 + 0.1% sodium hyaluronate eye drops Twice a day for 30 days
Eye Institute of Xiamen University; Eye Institute of Xiamen University, Senju Pharmaceutical Co., Ltd.
Sjogren's syndrome
 
 
CTRIPS, ChiCTR-IPR-15005990: Cyclosporine A in the Treatment of Interstitial Pneumonitis associated with Sjogren’s syndrome(): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial

Not yet recruiting
4
240
 
glucocorticoid+CsA ;glucocorticoid+placebo
Peking University People's Hospital; Level of the institution：, Hangzhou China-US East China pharmaceutical Co., Ltd.
Sjogren's syndrome
 
 
PromiseSS, ChiCTR-IPR-15005757: Prospective, Randomized, placebo-cOntrolled, double-blind, MultIcenter, parallel group Study to assess the Efficacy and safety of hydroxychloroquine in chinese patients with primary Sjogren's Syndrome

Not yet recruiting
4
400
 
Taking HCQ ;Nil
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Shanghai Zhongxi Pharmaceutical Co., Ltd.
primary Sjogren's Syndrome
 
 
ChiCTR-IPR-17013772: A Clinical Multi-center Study of Safety and Efficacy of Tacrolimus Eye Drops in Sjogren's Syndrome Dry Eye

Not yet recruiting
4
60
 
tacrolimus eye drops ;flurometholone eye drops
The Eye Hospital of Wenzhou Medical University; The Eye Hospital of Wenzhou Medical University, Supporting funds of the National Natural Science Foundation of China
Sjogren's Syndrome Dry Eye
 
 
ChiCTR1900022781: Follow-up study at four years after the end of clinical trial on the efficacy and safety of total glucosides of peony in the treatment of primary sjogren’s syndrome

Recruiting
4
180
 
TGP capsules
Department of Rheumatology and Immunology, Anhui Provincial Hospital; Ningbo Liwah Pharmaceutical Co., Ltd., Ningbo Liwah Pharmaceutical Co., Ltd.
Sjogren's Syndrome
 
 
ChiCTR1800019784: The metagenomic analysis of oral microflora in patients with primary Sjogren's syndrome before and after caries treatment and topical fluoridation

Recruiting
4
20
 
topical fluoridation; caries treatment ;topical fluoridation
Peking University School and Hospital of Stomatology; Peking University School and Hospital of Stomatology, Scientific research co-ordination fund
primary Sjogren's syndrome, dental caries
 
 
2021-001414-10: Response to corona vaccination in patients with primary Sjögren's syndrome

Ongoing
4
180
Europe
Dispersion for injection, Suspension for injection, Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]), COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
University Medical Center Groningen, Dutch Association of Sjögren patients (NVSP)
Primary Sjögren's syndrome, Primary Sjögren's syndrome, Diseases [C] - Immune System Diseases [C20]
 
 
ChiCTR1900022696: A prospective, controlled, randomized, open-label, single-center study for eramyd in the treatment of active sjogren's syndrome

Not yet recruiting
4
120
 
Iguratimod 25mg bid po ;hydroxychloroquine 0.2-0.4g/d+prednison0.2-0.5mg/kg.d
Shanghai Tongji Hospital; Shanghai Tongji Hospital, scientific research funds
Sjogren syndrome
 
 
ChiCTR2100052314: Effect of triamcinolone acetonide for parotid gland lavage on the salivary secretion of patients with Sjogren's syndrome

Not yet recruiting
4
54
 
Perfusing parotid gland with triamcinolone acetonide injection through parotid duct ;The parotid gland was perfused with normal saline through parotid duct
Affiliated Stomatological Hospital of Nanjing Medical University; Affiliated Stomatological Hospital of Nanjing Medical University, the National Natural Science Foundation of China (No. 81600908 and 81701491), the Nature Science Foundation of Jiangsu Province (No. BK2018040793 and BK20170152)
Sjogren syndrome
 
 
NCT04909255: Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Recruiting
4
50
RoW
mirabegron, Betmiga, oxybutynin, tolterodine, solifenacin, Ditropan, tartrate, vesicare
China Medical University Hospital
Sjogren's Syndrome, Overactive Bladder Syndrome
08/22
08/22
NCT04981145: The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Recruiting
4
78
RoW
Iguratimod Tablets, Hydroxychloroquine Sulfate Tablets
Second Affiliated Hospital, School of Medicine, Zhejiang University
Primary Sjögren's Syndrome
12/24
07/25
NCT05918406: Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

Completed
4
30
US
Nasal Guide
Oyster Point Pharma, Inc.
Dry Eye, Keratoconjunctivitis Sicca
08/23
08/23
NCT05700422: Nasal Spray Study in Sjogren's Dry Eye Disease

Completed
4
39
US
Varenicline Nasal Spray
University of Pennsylvania, Oyster Point Pharma, Inc.
Sjogren's Syndrome, Dry Eye
08/23
08/23
ChiCTR2500099615: Preliminary Study on the Clinical Efficacy and Mechanism of 0.05% Cyclosporine Eye Drops in the Treatment of Sj gren's Syndrome.

Completed
4
30
 
On top of the existing treatment, add 0.05% cyclosporine eye drops, four times a day.
Peking University First Hospital; Peking University First Hospital, Bethune Charitable Foundation, BCF
Sj gren's Syndrome
 
 
BRRPJS, NCT06410833: Belimumab After Rituximab in Resistant Primary Juvenile SS

Recruiting
4
15
RoW
Rituximab, Belimumab
Peking Union Medical College Hospital, Children's Hospital of Chongqing Medical University, Central South University, Shenzhen Children's Hospital, The First Hospital of Jilin University, Children's Hospital of The Capital Institute of Pediatrics, The Affiliated Hospital of Qingdao University, Children's Hospital of Nanjing Medical University, Children's Hospital of Fudan University, Shengjing Hospital, Shanghai Children's Hospital, Tianjin Children's Hospital
Sjogren's Syndrome, Pediatric ALL
12/25
12/26
NCT04835623: CEQUA for Sjogren's Syndrome Dry Eye

Completed
4
50
US
Cyclosporine 0.09% Ophthalmic Solution, Cequa Ophthalmic Product
Center for Ophthalmic and Vision Research, LLC, Sun Pharmaceutical Industries Limited
Dry Eye, Dry Eye Syndromes, Sjogren's Syndrome
03/24
03/24
RZVRheum, NCT05879419: Recombinant Herpes Zoster Vaccine in Patients with Autoimmune Rheumatic Diseases

Active, not recruiting
4
2005
RoW
Recombinant Herpes Zoster Vaccine (RZV), Shingrix®, MTX Discontinuation, MMF Discontinuation, Placebo, MTX maintain, MMF maintain
University of Sao Paulo General Hospital, GlaxoSmithKline
Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Vasculitis, Systemic, Juvenile Idiopathic Arthritis, Dermatomyositis, Juvenile, Behçet Disease
05/25
05/27
ChiCTR2200057578: Tofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trial

Not yet recruiting
4
120
 
Same dose of hydroxychloroquine sulfate as before ;Tofacitinib 5mg bid po+the same dose of hydroxychloroquine sulfate as before
Ningbo Medical Center Lihuili Hospital; Ningbo Medical Center Lihuili Hospital, Hisun biopharmaceutical.CO.,Ltd
Sjogren Syndrome
 
 
ChiCTR2300071950: Effect of acetylcysteine solution for salivary gland lavage on the salivary secretion of patients with Sjogren's syndrome

Not yet recruiting
4
51
 
Salivary gland irrigation with physiological saline through the opening of the salivary duct ;Salivary gland irrigation with acetylcysteine solution through the opening of the salivary duct ;N/A
The Fourth Affiliated Hospital of Nanjing Medical University ; The Fourth Affiliated Hospital of Nanjing Medical University, self-funding
Sjögren's syndrome
 
 
2014-003140-12: Leflunomide and Hydroxychloroquine combination therapy for primary Sjogren's Syndrome Leflunomide en Hydroxychloroquine combinatie therapie voor het primaire Syndroom van Sjogren

Ongoing
3
30
Europe
Leflunomide mylan, Plaquenil, Capsule, Leflunomide Mylan, Plaquenil
UMC Utrecht, ZonMw
Sjogren's Syndrome Syndroom van Sjogren, Sjogren's Syndrome Syndroom van Sjogren, Diseases [C] - Immune System Diseases [C20]
 
 
2017-001371-24: Intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies Immunoglobulines administrées par voie intraveineuse pour le traitement d’une neuropathie sensitive douloureuse compliquant un syndrome de Gougerot Sjögren primaire

Not yet recruiting
3
24
Europe
Solution for infusion, Privigen 100 mg/ml, solution pour perfusion
Hôpitaux Universitaires de Strasbourg, Hôpitaux universitaires de Strasbourg, CSL Behring
Primary Sjögren's syndrome associated painful sensory neuropathies Neuropathie sensitive douloureuse compliquant un syndrome de Gougerot Sjögren primaire, Primary Sjögren's syndrome associated painful sensory neuropathies Neuropathie sensitive douloureuse compliquant un syndrome de Gougerot Sjögren primaire, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-005687-22: A clinical study to investigate ianalumab is effective and safe in the treatment of active Sjögren`s syndrome

Ongoing
3
489
Europe
ianalumab, VAY736, Solution for injection in pre-filled syringe
Novartis Pharma AG, Novartis Pharma AG
Active Sjögren’s syndrome, Sjögren’s syndrome, Diseases [C] - Immune System Diseases [C20]
 
 
2020-005661-14: A clinical study to investigate if ianalumab is effective and safe in the treatment of active Sjögren`s syndrome

Ongoing
3
268
Europe
ianalumab, VAY736, Solution for injection in pre-filled syringe
Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Active Sjögren's syndrome, Sjögren's syndrome, Diseases [C] - Immune System Diseases [C20]
 
 
2022-002158-15: Treatment with tivanisiran for the dry eye in patients witht Sjögren Syndrome Tratamiento con tivanisirán para el ojo seco en pacientes con Síndrome de Sjögren

Not yet recruiting
3
200
Europe
Tivanisiran, SYL1001, Eye drops, solution
Sylentis SAU, Sylentis SAU
Dry Eye Disease Enfermedad de Ojo Seco, Ocular dryness Sequedad ocular, Diseases [C] - Eye Diseases [C11]
 
 
NCT04252209: the Effect of Mixture of Natural Products As Salivary Substitutes in Treatment Of Xerostomia

Completed
3
24
RoW
natural herbs of coconut, aloe vera, and pepperint, natural products, carboxy methyl cellulose, CMC
Cairo University
Sjogren's Syndrome, Xerostomia
11/22
03/23
NCT04819269: Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Completed
3
203
Europe, US
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
Sylentis, S.A.
Dry Eye Disease, Sjögren Syndrome
12/23
12/23
NCT06931041: Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial

Active, not recruiting
3
25
RoW
insulin lispro, Autologous serum
Instituto de Oftalmología Fundación Conde de Valenciana
Dry Eye, Sjogren Syndrome
06/25
06/25
HZNP-DAZ-303, NCT06245408: A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Recruiting
3
435
Europe, Canada, Japan, US, RoW
Dazodalibep, VIB 4920, MEDI4920, Placebo
Amgen
Sjögren's Syndrome (SS)
11/26
11/26
ARGX-113-2306, NCT06684847: A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome

Recruiting
3
580
US
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Primary Sjogrens Disease
07/27
07/28
DAFFODIL, NCT06741969: Nipocalimab in Moderate to Severe Sjogren's Disease

Recruiting
3
600
Europe, Japan, US, RoW
Nipocalimab, JNJ-80202135, JNJ-86507083, M281, Placebo, Standard of care treatment
Janssen Research & Development, LLC
Sjogrens Syndrome
01/28
05/30
NCT06747949: A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Recruiting
3
844
US
Dazodalibep, AMG 611
Amgen
Sjögren's Syndrome
08/29
08/29
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
506
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
TINISS, NCT03700138: Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies

Recruiting
3
24
Europe
Privigen® 100mg/ml at the dose of 2g/kg of body weight, NaCl 0,9%
University Hospital, Strasbourg, France
Primary Sjögren's Syndrome Painful Sensory Neuropathies
12/25
07/26
NCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Recruiting
3
621
Europe, Canada, Japan, US, RoW
Dazodalibep, VIB 4920, MEDI 4920, Placebo
Amgen
Sjogren's Syndrome
08/26
08/26
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
POETYK SjS-1, NCT05946941: A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

Recruiting
3
756
Europe, Canada, Japan, US, RoW
Deucravacitinib, BMS-986165, Placebo
Bristol-Myers Squibb
Sjögren's Syndrome
11/26
11/28
NCT05673993: A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Active, not recruiting
3
381
RoW
Telitacicept 80 mg, RC 18 80 mg, Telitacicept 160 mg, RC 18 160 mg, Placebo
RemeGen Co., Ltd.
Primary Sjogren's Syndrome
12/27
06/28
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
NCT05005806: Fish Oil (Omega 3 ) in Sjogren's Syndrome

Completed
2/3
100
RoW
Omega 3 fatty acid, Placebo
Hawler Medical University
Sjogren's Syndrome
02/23
02/23
 

Download Options